Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

C-reactive protein (CRP), interferon gamma-inducible protein 10 (IP-10), and lipopolysaccharide (LPS) are associated with risk of tuberculosis after initiation of antiretroviral therapy in resource-limited settings.

Tytuł:
C-reactive protein (CRP), interferon gamma-inducible protein 10 (IP-10), and lipopolysaccharide (LPS) are associated with risk of tuberculosis after initiation of antiretroviral therapy in resource-limited settings.
Autorzy:
Tenforde MW; Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.
Gupte N; Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.
Dowdy DW; Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, United States of America.
Asmuth DM; University of California Davis Medical Center, Sacramento, California, United States of America.
Balagopal A; Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.
Pollard RB; University of California Davis Medical Center, Sacramento, California, United States of America.
Sugandhavesa P; Research Institute for Health Sciences, Chiang Mai University, Chiang Mai, Thailand.
Lama JR; Asociación Civil Impacta Salud y Educación (IMPACTA) Peru Clinical Trials Unit, Lima, Peru.
Pillay S; Nelson Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa.
Cardoso SW; Instituto de Pesquisa Clínica Evandro Chagas, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil.
Pawar J; National AIDS Research Institute, Pune, India.
Santos B; Hospital Nossa Senhora da Conceição, Porto Alegre, Brazil.
Riviere C; Les Centres Groupe Haïtien d'Etude du Sarcome de Kaposi et des Infections Opportunites (GHESKIO), Port-Au-Prince, Haiti.
Mwelase N; University of Witwatersrand, Johannesburg, South Africa.
Kanyama C; University of North Carolina Project, Kamuzu Central Hospital, Lilongwe, Malawi.
Kumwenda J; Malawi College of Medicine-Johns Hopkins University Research Project, Blantyre, Malawi.
Hakim JG; University of Zimbabwe, Harare, Zimbabwe.
Kumarasamy N; Y.R. Gaitonde Centre for AIDS Research and Education (YRG CARE), Chennai, India.
Bollinger R; Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.
Semba RD; Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.
Campbell TB; University of Colorado Denver School of Medicine, Aurora, Colorado, United States of America.
Gupta A; Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America; Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, United States of America.
Corporate Authors:
ACTG PEARLS and NWCS 319 Study Group
Źródło:
PloS one [PLoS One] 2015 Feb 26; Vol. 10 (2), pp. e0117424. Date of Electronic Publication: 2015 Feb 26 (Print Publication: 2015).
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Język:
English
Imprint Name(s):
Original Publication: San Francisco, CA : Public Library of Science
MeSH Terms:
AIDS-Related Opportunistic Infections/*blood
Anti-Retroviral Agents/*adverse effects
C-Reactive Protein/*metabolism
Chemokine CXCL10/*blood
Lipopolysaccharides/*blood
Tuberculosis/*blood
AIDS-Related Opportunistic Infections/epidemiology ; Adult ; Developing Countries ; Female ; Humans ; Incidence ; Male ; Risk ; Tuberculosis/epidemiology
References:
J Acquir Immune Defic Syndr. 2010 Nov;55(3):316-22. (PMID: 20581689)
Eur Respir J. 2010 Dec;36(6):1488-90. (PMID: 21119209)
Clin Dev Immunol. 2011;2011:758350. (PMID: 21197091)
J Acquir Immune Defic Syndr. 2011 Mar 1;56(3):230-8. (PMID: 21239993)
J Infect Dis. 2011 Mar 15;203(6):780-90. (PMID: 21252259)
J Acquir Immune Defic Syndr. 2011 Apr;56(4):349-55. (PMID: 20926954)
PLoS One. 2011;6(4):e18580. (PMID: 21494598)
J Infect Dis. 2011 Jun 1;203(11):1637-46. (PMID: 21592994)
J Infect Dis. 2011 Sep 15;204(6):893-901. (PMID: 21849286)
J Acquir Immune Defic Syndr. 2011 Aug 1;57(4):311-8. (PMID: 21423023)
Int J Infect Dis. 2012 Dec;16(12):e855-9. (PMID: 22959355)
Asian Pac J Trop Med. 2012 Dec;5(12):986-90. (PMID: 23199719)
BMC Infect Dis. 2013;13:48. (PMID: 23360117)
J Infect. 2013 Apr;66(4):357-65. (PMID: 23178506)
Trans R Soc Trop Med Hyg. 2013 Apr;107(4):235-42. (PMID: 23324313)
J Infect Dis. 2013 May 1;207(9):1370-8. (PMID: 23319741)
Int J Tuberc Lung Dis. 2013 May;17(5):636-43. (PMID: 23575330)
J Immunol. 2002 Apr 1;168(7):3195-204. (PMID: 11907072)
Immunology. 2003 Mar;108(3):365-74. (PMID: 12603603)
AIDS. 2005 Dec 2;19(18):2109-16. (PMID: 16284460)
Arch Intern Med. 2006 Jan 9;166(1):64-70. (PMID: 16401812)
AIDS. 2007 Oct 1;21(15):2067-75. (PMID: 17885297)
Clin Infect Dis. 2007 Dec 1;45(11):1518-21. (PMID: 17990236)
Microbiology. 2008 Jun;154(Pt 6):1813-24. (PMID: 18524936)
PLoS One. 2012;7(5):e37350. (PMID: 22606361)
Trans R Soc Trop Med Hyg. 2012 Jun;106(6):363-70. (PMID: 22521216)
PLoS One. 2012;7(6):e38501. (PMID: 22693640)
PLoS One. 2012;7(8):e41258. (PMID: 22870212)
Viral Immunol. 2012 Aug;25(4):333-7. (PMID: 22788418)
PLoS Med. 2012;9(7):e1001270. (PMID: 22911011)
Lancet Infect Dis. 2008 Aug;8(8):516-23. (PMID: 18652998)
AIDS. 2008 Oct 1;22(15):2035-8. (PMID: 18784466)
Antivir Ther. 2008;13(8):969-76. (PMID: 19195322)
Hum Immunol. 2009 Feb;70(2):110-5. (PMID: 19100801)
AIDS Res Hum Retroviruses. 2009 Feb;25(2):183-91. (PMID: 19239357)
Am J Clin Nutr. 2009 Jul;90(1):225-33. (PMID: 19474129)
AIDS. 2010 Jan 16;24(2):323-5. (PMID: 20010069)
Int J Tuberc Lung Dis. 2010 Mar;14(3):318-23. (PMID: 20132623)
Nat Rev Microbiol. 2010 Mar;8(3):242; author reply 242. (PMID: 20084059)
J Infect Dis. 2010 Apr 15;201(8):1150-4. (PMID: 20199244)
PLoS One. 2010;5(9):e12577. (PMID: 20830287)
PLoS Med. 2012;9(8):e1001290. (PMID: 22936892)
PLoS One. 2012;7(9):e44944. (PMID: 23028695)
Tuberculosis (Edinb). 2012 Nov;92(6):513-20. (PMID: 22824465)
PLoS One. 2012;7(11):e43438. (PMID: 23144772)
PLoS One. 2011;6(11):e26545. (PMID: 22132075)
PLoS One. 2011;6(12):e28691. (PMID: 22220193)
Grant Information:
R01 AI45462 United States AI NIAID NIH HHS; UM1 AI068634 United States AI NIAID NIH HHS; R01 DA016078 United States DA NIDA NIH HHS; UM1 AI069518 United States AI NIAID NIH HHS; U01 AI069450 United States AI NIAID NIH HHS; U01 AI068636 United States AI NIAID NIH HHS; UM1 AI069463 United States AI NIAID NIH HHS; UM1 AI069450 United States AI NIAID NIH HHS; AI069450 United States AI NIAID NIH HHS; AI68636 United States AI NIAID NIH HHS; UM1 AI069423 United States AI NIAID NIH HHS; UM1 AI068636 United States AI NIAID NIH HHS; R01 AI045462 United States AI NIAID NIH HHS
Substance Nomenclature:
0 (Anti-Retroviral Agents)
0 (CXCL10 protein, human)
0 (Chemokine CXCL10)
0 (Lipopolysaccharides)
9007-41-4 (C-Reactive Protein)
Entry Date(s):
Date Created: 20150227 Date Completed: 20160118 Latest Revision: 20201217
Update Code:
20240104
PubMed Central ID:
PMC4342263
DOI:
10.1371/journal.pone.0117424
PMID:
25719208
Czasopismo naukowe
Objective: The association between pre-antiretroviral (ART) inflammation and immune activation and risk for incident tuberculosis (TB) after ART initiation among adults is uncertain.
Design: Nested case-control study (n = 332) within ACTG PEARLS trial of three ART regimens among 1571 HIV-infected, treatment-naïve adults in 9 countries. We compared cases (participants with incident TB diagnosed by 96 weeks) to a random sample of controls (participants who did not develop TB, stratified by country and treatment arm).
Methods: We measured pre-ART C-reactive protein (CRP), EndoCab IgM, ferritin, interferon gamma (IFN-γ), interleukin 6 (IL-6), interferon gamma-inducible protein 10 (IP-10), lipopolysaccharide (LPS), soluble CD14 (sCD14), tumor necrosis factor alpha (TNF-α), and CD4/DR+/38+ and CD8/DR+/38+ T cells. Markers were defined according to established cutoff definitions when available, 75th percentile of measured values when not, and detectable versus undetectable for LPS. Using logistic regression, we measured associations between biomarkers and incident TB, adjusting for age, sex, study site, treatment arm, baseline CD4 and log10 viral load. We assessed the discriminatory value of biomarkers using receiver operating characteristic (ROC) analysis.
Results: Seventy-seven persons (4.9%) developed incident TB during follow-up. Elevated baseline CRP (aOR 3.25, 95% CI: 1.55-6.81) and IP-10 (aOR 1.89, 95% CI: 1.05-3.39), detectable plasma LPS (aOR 2.39, 95% CI: 1.13-5.06), and the established TB risk factors anemia and hypoalbuminemia were independently associated with incident TB. In ROC analysis, CRP, albumin, and LPS improved discrimination only modestly for TB risk when added to baseline routine patient characteristics including CD4 count, body mass index, and prior TB.
Conclusion: Incident TB occurs commonly after ART initiation. Although associated with higher post-ART TB risk, baseline CRP, IP-10, and LPS add limited value to routine patient characteristics in discriminating who develops active TB. Besides determining ideal cutoffs for these biomarkers, additional biomarkers should be sought that predict TB disease in ART initiators.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies